高效液相色谱法测定香砂养胃颗粒中橙皮苷含量

目的:建立香砂养胃颗粒中橙皮苷的含量测定方法.方法:高效液相色谱法(HPLC法),以磷酸盐缓冲液-乙腈(4:1)为流动相,检测波长为283 nm.结果:橙皮苷进样浓度在0.01～0.20 mg/mL范围内与峰面积线性关系良好,r=0.999 7,平均回收率为99.9%,RSD=1.73%(n=6).结论:HPLC法简便、快速、灵敏、准确,可用于香砂养胃颗粒的质量控制.     

高效液相色谱法测定藿香正气口服液中橙皮苷含量

目的:建立一种藿香正气口服液测定含量的方法,有效地控制本制剂的质量.方法:采用高效液相色谱法(HPLC法),以十八烷基硅烷键合硅胶为填充剂,以甲醇-冰醋酸-水(35:4:61)为流动相,检测波长283 nm,流速为0.8 mL/min.结果:样品中橙皮苷得到了很好的分离,橙皮苷进样量在0.5～2.5μg内与峰面积线性关系良好,r=0.999 6,回收率为99.85%,RSD为0.76%.结论:HPLC法准确、稳定,可用于控制本制剂的质量.     

高效液相色谱法测定百梅止咳颗粒中橙皮苷的含量

目的 建立高效液相色谱法(HPLC)测定百梅止咳颗粒中橙皮苷的含量.方法 采用色谱柱Diamonsil C18(5μm,4.6 mm×250mm);流动相:甲醇-醋酸-水(35:4:61);流速:1.0 ml/min;检测波长:284 nm;柱温:35℃.结果 橙皮苷进样量在0.202～2.020 μg范围内线性良好(r=0.9998,n=5),平均加样回收率达102.67%,相对标准偏差值(RSD)为1.42%.结论 HPLC简便可行,重现性好,可用于百梅止咳颗粒的质量控制.     

高效液相色谱法测定健胃消食片中橙皮苷的含量

目的:建立健胃消食片中橙皮苷含量的测定方法,考察市售产品的质量.方法:超声提取,高效液相色谱法( HPLC法)测定健胃消食片中橙皮苷的含量,流动相为乙腈-水-醋酸( 18 ∶ 82 ∶ 2),检测波长为 284 nm,流速为 1.2 mL/min,按外标峰面积法计算含量.结果:橙皮苷能与其他组分分离,线性范围为 0.06～ 0.48 μ g/mL, r=0.999 4,回收率为 103.4%, 5批市售健胃消食片中橙皮苷的含量为 0.17～ 0.35 mg/g.结论: HPLC法可用于健胃消食片的质量控制.     

高效液相色谱法测定妇科白带片中橙皮苷的含量

目的 建立妇科白带片中橙皮苷的含量测定方法.方法 色谱柱:Diamond C18(4.6 mm×200 mm,5 μ m),流动相:乙睛-0.1%磷酸溶液(21:79),流速1.0ml/min,检测波长283nm.结果 橙皮苷在0.0668～0.6012 μ g范围内呈现良好的线性关系,r=0.9994,平均回收率为96.96%,RSD为1.01%.结论 本方法简便、快速、准确,分离效果好.     

高效液相色谱法测定舒通颗粒中橙皮苷的含量

目的:建立舒通颗粒中橙皮苷的含量测定方法.方法:采用高效液相色谱法 (HPLC法 ),以十八烷基硅烷键合硅胶为固定相,流动相为乙腈- 0.1%磷酸( 22:78);检测波长为 283 nm.结果:样品中橙皮苷得到了很好分离,橙皮苷对照品的线性范围是 0.13～ 1.30 μ g, r=0.999 8,平均加样回收率为 98.71%, RSD为 1.55%.结论:该方法结果准确、重现性好,可用于该制剂的质量控制.     

橘红片中橙皮苷含量测定方法研究

目的:建立HPLC法测定橘红片中橙皮苷含量的方法。方法:采用高效液相色谱法对橘红片中橙皮苷进行含量测定;色谱柱为WatersVP-ODS-C18,流动相为甲醇-水-冰醋酸(35:61:4);流速为1.0mL/min,检测波长283nm。结果:橙皮苷的进样量在0.3964～2.3784μg范围内呈良好的线性关系(r=0.99996),平均加样回收率为99.92%,RSD为0.3%(n=6)。结论:该方法结果准确,重现性好,可用于测定橘红片中橙皮苷含量。     

HPLC法测定肾乐胶囊中橙皮苷的含量

目的:建立HPLC测定肾乐胶囊中橙皮苷含量的方法。方法:采用HPLC法对肾乐胶囊中橙皮苷进行含量测定。测定条件:采用Diamonsil C18色谱柱(250 mm×4.6 mm,5μm),流动相为甲醇-水(40∶60),检测波长:283 nm,流速:1.0mL.min-1,柱温:35℃。结果:在本法条件下,橙皮苷与其他杂质峰分离良好,进样量在8.544～85.44 mg.mL-1与峰面积呈良好的线性关系(r=0.999 9),平均加样回收率为101.6%,RSD为0.54%(n=6)。三个批次的肾乐胶囊中橙皮苷的平均含量为2.75 mg.g-1。结论:采用该方法测定肾乐胶囊中的橙皮苷,简便易行,结果准确,可作为肾乐胶囊的质量控制方法。     

蛇胆陈皮胶囊中橙皮苷的HPLC测定

建立了测定蛇胆陈皮胶囊中橙皮苷的HPLC法.色谱柱为C18柱,乙腈-水-磷酸(210:790:0.1)为流动相,检测波长283nm.橙皮苷在0.14～1.09μg范围内呈良好的线性关系(r=0.9999),平均回收率为99.8%(RSD=1.7%).     

HPLC法测定妇科白带胶囊中橙皮苷的含量

目的建立妇科白带胶囊中橙皮苷的含量测定方法。方法以SHIMADZU—VP—ODS（4．6mm×250mm,5斗m）为分析柱,柱温30℃,流动相：乙腈-4％冰醋酸溶液（20：80流速：1．0ml·min-1;检测波长：283nm;进样量10μl。结果橙皮苷在40．2～1005ng范围内呈良好线性关系,相关系数为0．9999,平均回收率为98．6％（n=-9,RSD=1．6％）。结论该方法专属性好、准确度高,可用于妇科白带胶囊的质量控制。     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Nachweis einiger Heilmittel in der Kniegelenksynovialflüssigkeit

Zusammenfassung Mittels Gaschromatographie und Dünschichtchromatographie wiesen die Autoren 11 Substanzen nach, welche durch Injektion oder nach Verabreichung per os in die Kniegelenksynovialflüssigkeit eindrangen. In ihrer Aufstellung konnten sie eine direkte Beziehung zwischen Struktur sowie chemischphysikalischen Eigenschaften der Substanz und ihrer Fähigkeit, aus dem Blut in die Kniegelenksynovialflüssigkeit einzudringen, nicht nachweisen, außer der Tatsache, daß Substanzen mit starker Affinität zu Eiweißstoffen erst in höheren Dosen nachweisbar waren.     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.     

Gender-related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders

This study explored gender-related symptoms and correlates of alcohol dependence in a crosssectional study of 150 men and 150 women with a lifetime diagnosis of alcohol use disorders (AUD). Participants were recruited in equal numbers from treatment settings, correctional centres and the general community. Standardized measures were used to determine participants' use of substances, history of psychiatric disorders and psychosocial stress, their sensation seeking and family history of substance use and mental health disorders. Multivariate analyses were used to detect patterns of variables associated with gender and the lifetime severity of AUD. Men had a longer history of severe AUD than women. Women had similar levels of alcohol dependence and medical and psychological sequelae as men, despite 6 fewer years of AUD. More women than men had a history of severe psychosocial stress, severe dependence on other substances and antecedent mental health problems, especially mood and anxiety disorders. There were differences in family history of alcohol-related problems approximating same-gender aggregation. The severity of a lifetime AUD was predicted by its earlier age at onset and the occurrence of other disorders, especially anxiety, among both men and women. The limitations in the generalizability of these findings due to sample idiosyncrasies are discussed.     

Biochemical and molecular characterisation of cubozoan protein toxins

Class Cubozoa includes several species of box jellyfish that are harmful to humans. The venoms of box jellyfish are stored and discharged by nematocysts and contain a variety of bioactive proteins that are cytolytic, cytotoxic, inflammatory or lethal. Although cubozoan venoms generally share similar biological activities, the diverse range and severity of effects caused by different species indicate that their venoms vary in protein composition, activity and potency. To date, few individual venom proteins have been thoroughly characterised, however, accumulating evidence suggests that cubozoan jellyfish produce at least one group of homologous bioactive proteins that are labile, basic, haemolytic and similar in molecular mass (42-46 kDa). The novel box jellyfish toxins are also potentially lethal and the cause of cutaneous pain, inflammation and necrosis, similar to that observed in envenomed humans. Secondary structure analysis and remote protein homology predictions suggest that the box jellyfish toxins may act as α-pore-forming toxins. However, more research is required to elucidate their structures and investigate their mechanism(s) of action. The biological, biochemical and molecular characteristics of cubozoan venoms and their bioactive protein components are reviewed, with particular focus on cubozoan cytolysins and the newly emerging family of box jellyfish toxins.     

Dose tolerability of chronically inhaled voriconazole solution in rodents

Invasive pulmonary aspergillosis (IPA) is a fungal disease of the lung associated with high mortality rates in immunosuppressed patients despite treatment. Targeted drug delivery of aqueous voriconazole solutions has been shown in previous studies to produce high tissue and plasma drug concentrations as well as improved survival in a murine model of IPA. In the present study, rats were exposed to 20 min nebulizations of normal saline (control group) or aerosolized aqueous solutions of voriconazole at 15.625 mg (low dose group) or 31.25 mg (high dose group). Peak voriconazole concentrations in rat lung tissue and plasma after 3 days of twice daily dosing in the high dose group were 0.85 ± 0.63 μg/g wet lung weight and 0.58 ± 0.30 μg/mL, with low dose group lung and plasma concentrations of 0.38 ± 0.01 μg/g wet lung weight and 0.09 ± 0.06 μg/mL, respectively. Trough plasma concentrations were low but demonstrated some drug accumulation over 21 days of inhaled voriconazole administered twice daily. Following multiple inhaled doses, statistically significant but clinically irrelevant abnormalities in laboratory values were observed. Histopathology also revealed an increase in the number of alveolar macrophages but without inflammation or ulceration of the airway, interstitial changes, or edema. Inhaled voriconazole was well tolerated in a rat model of drug inhalation.